Acute Invasive Aspergillosis Treatment Market Five Years Forecast Skeleton With Key Companies

According to the Centers for Disease Control and Prevention, the epidemiology of invasive aspergillus infection is dependent upon increasing number of solid organ transplants, stem cell transplant, and newer immunosuppressive agents, 2017. According to Organ Procurement and Transplantation Network (OPTN), around 8,500 organ transplants have been performed in 2018 and the number is expected to grow in the near future. These factors are expected to support the growth of the acute invasive aspergillosis treatment market. Patients who undergo organ transplant procedure are often prescribed immunosuppressant medications, which increases their susceptibility to aspergillosis infection. Similarly, patients in the advanced stages of AIDS are also highly susceptible to opportunistic infections such as aspergillosis.

According to the World Health Organization (WHO), around 36.7 million people were found suffering from HIV in 2016. Extended use of corticosteroids further weakens the immune system, thus increasing the risk of developing such infections. This in turn, is increasing the demand for acute invasive aspergillosis treatment over the forecast period. According to British Infection Association, the high risk population for invasive aspergillosis includes patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT), autologous HSCT patients, solid organ transplant patients as well as AIDS patients, patients suffering from acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, non-Hodgkin lymphoma, and myeloma patients. According to WHO, Cancer is the second-leading cause of death globally, and the disease caused 8.8 million deaths in 2015. Rising incidence of various types of cancers, is in turn expected to support growth of the global acute invasive aspergillosis treatment market.

Get HOLISTIC Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1520

The U.S. Food & Drug Administration (FDA) is increasingly approving several drugs for the treatment of this infection. For instance, Isavuconazonium, a prodrug form of Isavuconazole was approved by the FDA in 2015. Astellas Pharma US, Inc. markets Isavuconazonium under the brand name Cresemba. Astellas Pharma partnered with Basilea Pharmaceutica International Ltd. for license, co-development, and co-promotion of Isavuconazole (Cresemba), in 2010. In 2014, Basilea Pharmaceutica International Ltd. received full rights to sell Isavuconazole in all markets outside of the U.S. and Canada, and Astellas Pharma responsible for U.S. and Canada markets. Moreover, Basilea Pharmaceutica Ltd. partnered with Asahi Kasei Pharma for Isavuconazole development, licensing, and marketing in Japan (responsibility of Asahi Kasei), in 2016. The global acute invasive aspergillosis treatment market is expected to be significantly impacted over the forecast period as the drug Cresemba will expire in 2020. As generic manufacturers enter the market, the prices are expected to drop and volumes are expected to increase over the forecast period.

However, drug resistance to antifungal medications is widely witnessed during treatment of aspergillosis infections, which is expected to restrain growth of the acute invasive aspergillosis treatment market over the forecast period.

Acute Invasive Aspergillosis Treatment Market Insights

Most antifungal medications have lost their patent protection over the last few years and generic versions of these products are increasingly being made available by generic drug manufacturers, which in turn is supporting growth of the acute invasive aspergillosis treatment market. Manufacturers such as Amneal Pharmaceuticals, Sandoz Inc., Glenmark Pharmaceuticals Ltd., Mylan Pharmaceuticals, Inc., and Teva Pharmaceuticals offer generic versions of antifungal medications in the acute invasive aspergillosis treatment market. Independent organizations are dedicated towards research and development of novel antifungal therapies. For instance, F2G, an established U.K.-based biotechnology company is focused on the discovery and development of novel drugs for the treatment of serious fungal diseases such as acute invasive aspergillosis.

Key players operating in the global acute invasive aspergillosis treatment market include GlaxoSmithKline, Mylan Pharmaceuticals, Inc., Novartis AG, Abbott laboratories, Eli Lilly and Company, AstraZeneca Plc, Pfizer, Inc., Johnson & Johnson, Takeda Pharmaceutical Company Ltd., Astellas, and Basilea Pharmaceutica International Ltd.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1520

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.